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Purpose: Novel osmium anticancer drugs are under evaluation 
that promise superior properties with respect to traditional 
Pt based drugs [1]. Even selective action against cancer stem 
cells has been reported [2]. Radiotracer and nuclear 
medicine techniques could help in the development and 
application of these drugs. 191Os is an osmium radioisotope 
well suited for this purpose with excellent properties for 
imaging and therapy. We discuss calculated Auger electron 
spectra, production methods and prospects of applications of 
191Os. 
Methods: 191Os (T1/2=15.4 d) decays to short-lived (T1/2=4.9 s) 
191mIr that emits 129 keV γ rays (26.5% intensity) well suited 
for SPECT imaging. In the past 191Os/191mIr generators [3] were 
used to provide 191mIr for first pass radionuclide 
angiocardiography [4] or studies of renal blood flow [5], but 
no direct use of 191Os has been reported so far. Among all 
known β-emitters with days to weeks half-life 191Os sticks up 
with the lowest β decay energy of only 38 keV on average 
(114 keV maximum), corresponding to a range of about one 
cell diameter. This β radiation is supplemented by abundant 
emission of short-range conversion and Auger electrons (< 60 
keV). Consequently 191Os has also potential as therapeutic 
isotope. The Auger electron spectrum of this decay was 
calculated using the methodology described in Ref. [6]. 
Results: The figure shows the calculated electron energy 
spectrum in the β- decay of 191Os (red, left scale) and in the 
internal transition decay of 191mIr (blue and yellow, right 
scale). 
 
 
Upon β- decay of 191Os the nuclear recoil of 191mIr is <0.4 eV, 
thus avoiding breakage of chemical bonds and uncontrolled 
translocation of 191mIr, provided the chemical valency change 
is tolerated. 
Direct production by 190Os(n,γ)191Os in a high thermal neutron 
flux of 1.5⋅1015 n.cm-2s-1 in ILL’s high flux reactor [7] reaches 
specific activities of ≈10 GBq/mg (≈2 MBq/µmol) after 5 days 
of irradiation. 
For Os drug dosages similar to cisplatin dosage this specific 
activity is by far sufficient for preclinical and clinical SPECT 
imaging. Even shorter irradiation times can be used to 
minimize co-produced activities (192Ir, etc.). 
Conclusions: Reactor-produced 191Os has great potential as 
radiotracer for in vitro studies of sub-cellular distribution of 
Os based drugs, for preclinical and clinical in vivo studies of 
pharmacokinetics of Os based drugs and eventually even for 
combined radionuclide-chemotherapy against particularly 
resistant tumors. 
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In 1999 to 2011, 249 cancer patients received 
boronophenylalanine (BPA)-mediated boron neutron capture 
therapy (BNCT) in Finland. Over one hundred of these 
patients were treated within the context of clinical trials. 
The purpose of the trials was to investigate the efficacy and 
safety of BNCT in the treatment of malignant gliomas (newly 
diagnosed or gliomas that progressed after surgery and 
radiotherapy) [1,2], and inoperable head-and-neck cancers 
that had recurred locally after external radiotherapy [3,4]. 
In BNCT, the absorbed radiation dose results from four main 
components: 1) the therapeutically desired high-LET 
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radiation dose from the 10B(n,α)7Li reaction, 2) the 
intermediate-LET proton dose released from the 14N(n,p)14C 
reaction in tissue, 3) the intermediate-LET protons released 
from the 1H(n,n’)p reaction in tissue, and 4) the low-LET 
photon dose mainly from the 1H(n,γ) reaction in tissue, but in 
part also from minor photon contamination in the neutron 
beam.  
Conventionally, the biologically effective “photon 
radiotherapy equivalent” dose has been derived from 
multiplying each dose component by a constant relative 
biological effectiveness (RBE) factor, or in the case of the 
boron dose, the compound biological effectiveness (CBE) 
factor. The estimations for the RBE and the CBE are obtained 
from cell culture studies and irradiation with photons, BNCT 
beam alone, and the beam in the presence of the boron 
compound [5]. The RBE and CBE factors are applied as fixed, 
although they depend on the cumulative irradiation time and 
the dose rate, and, ideally, they should be derived for each 
irradiation component individually. Furthermore, the 
radiation dose components have synergistic effects. The 
conventional fixed RBE-based dose calculation in BNCT tends 
to lead to unrealistically high estimated tumor doses, which 
may not be reflected in clinical outcomes and may not be 
comparable with photon irradiation data. 
Recently, an alternative method for calculating the effective 
dose was proposed [6]. The photon-isoeffective dose 
calculation formalism takes into account the dose rate and 
the cumulative dose per fraction in a modified linear-
quadratic model, and it also considers the synergistic 
interactions between different radiation components. The 
isoeffective dose calculation formalism predicted the 
response of melanoma lesions to BNCT better than the fixed 
RBE approach. 
In this study the tumor doses calculated with the RBE model 
and using the photon-isoeffective formalism are correlated 
with the clinical responses of the patients treated with BNCT 
in Finland. For glioma patients, the doses are compared with 
the overall survival time, whereas for patients with head-
and-neck cancer, tumor responses are evaluated. The BNCT 
dose response rates are compared with those obtained with 
conventional radiotherapy and responses reported in similar 
patient groups.    
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Single dose radiotherapy (SDRT), facilitated by image 
guidance and intensity modulation technologies that improve 
precision in tumor targeting to reduce risk of normal tissue 
toxicity, has revolutionized cancer treatment with local 
control rates ≥90%, even in tumors resistant to conventional 
fractionation. While classic radiobiology focuses on response 
of tumor cells rather than non-tumor microenvironmental 
cells, initial pre-clinical studies in our lab found disruption of 
tumor vasculature obligate for SDRT cure. This endothelial 
cell dysfunction results from activation of acid 
sphingomyelinase (ASMase), converting sphingomyelin to the 
second messenger ceramide in endothelial plasma 
membranes, events inhibitable by VEGF-121 or VEGF-165. 
Conversely, precisely timed delivery of anti-angiogenic 
agents, such as anti-VEGFR2 Ab DC101 (Imclone), de-
represses ASMase activity, synergistically increasing SDRT-
induced ceramide elevation, enhancing endothelial 
dysfunction. That ceramide is critical for anti-angiogenic 
radiosensitization is evidenced by nt i-ceramide Ab inhibition 
of DC101-enhanced endothelial damage and 
radiosensitization. These results translate in vivo, as anti-
VEGFR2 DC101 or anti-VEGF G6-31 (Genentech) 
synergistically increase SDRT-induced endothelial injury in 
numerous solid tumor types, only if delivery timed to 
maximally enhance ASMase signaling. In contrast, tumors in 
asmase-/- mice, which provide damage-resistant vasculature, 
are radioresistant and unaffected by either anti-angiogenic 
agent. This presentation will review fundamentals of this 
“New Biology” and present unpublished data that define 
mechanism of coupling of ceramide-driven endothelial 
dysfunction to DNA repair in tumor cells.  
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Lung cancer is the leading cause of cancer-related death in 
the United States and throughout the world. Although overall 
mortality rates from lung cancer in the United States have 
dropped from 85% two decades ago to 70% in 2015, tumor 
control and survival outcomes after standard therapy are still 
poor.  
Early detection involving the use of low-dose spiral computed 
tomography (CT) among former or current smokers led to a 
20% reduction in the rate of lung-cancer death in these 
individuals. Early stage lung cancer can be cured in some 
patients by stereotactic body radiation therapy SBRT). 
Advancement of sophisticated radiation treatment equipment 
and understanding physics of utilization of the equipment for 
SBRT rapidly became clinical application for the primary lung 
or hepatic lesions as well as or other metastatic lesions. 
Because of high dose per fraction, technical aspects and 
quality assurance to deliver the radiation to the tumor 
precisely and avoid high dose of radiation to the critical 
surrounding normal tissue are critical issues for SBRT.  
To understand tumor motion and control tumor motion have 
been major challenge for mainly lung lesions. To visualize 
hepatic lesion or other metastatic lesions e.g pancreas or 
soft tissue can be difficult without contrast enhancement or 
fiducial markers. The most challenging part of SBRT in 
addition to controlling tumor motion is lesions to be treated 
by this technique close to the critical organs e.g. blood 
vessels, brachial plexus, esophagus, major air way etc.  
Technologic advancements of imaging and radiotherapy to 
conform the gross target volume(GTV) with tighter margins 
but adequate clinical targeted volume (CTV) and planning 
tumor volume (PTV) considering daily set up variations which 
are supposed to minimize the dose to nearby normal tissues. 
Thus the technical advancement such as intensity modulated 
radiotherapy (IMRT) compared to 2 or 3 dimensional 
radiotherapy  improved outcomes among patients with locally 
advanced lung cancer, as has the addition of concurrent 
chemotherapy to radiation therapy. Further improvements 
are expected from the use of charged particle therapy with 
protons or other particles; randomized comparisons of proton 
therapy vs. intensity-modulated photon radiation therapy for 
lung cancer are underway in the United States.  
Approximately 50% of Non-Small Cell Lung Cancer patients 
have Adenocarcinoma Histology. 
Among the patients with Adenocarcinoma of Lung, 50% of 
them have genetic mutation. If they have ALK, EGFR, K-Ras 
or B-Raf mutation, we can target the mutated genes. 
For many years, immunomodulation or immunotherapy as a 
means of cancer therapy has been studied. Cancer cells are 
well known to have the ability to bypass immune surveillance 
through a variety of different mechanisms, including reduced 
expression of tumor antigens, downregulation of major 
histocompatibility complex (MHC) class I and II molecules for 
tumor antigen presentation, secretion of immunosuppressive 
cytokines such as tumor growth factor-beta (TGF-β), 
recruitment or induction of immunosuppressive cells such as 
